BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33710713)

  • 21. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
    Yan J; Zhou C; Guo K; Li Q; Wang Z
    J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A five lncRNA signature for prognosis prediction in hepatocellular carcinoma.
    Sun Y; Zhang F; Wang L; Song X; Jing J; Zhang F; Yu S; Liu H
    Mol Med Rep; 2019 Jun; 19(6):5237-5250. PubMed ID: 31059056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.
    Ma B; Li Y; Ren Y
    Cancer Med; 2020 Jan; 9(1):335-349. PubMed ID: 31743579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prognostic 11 long noncoding RNA expression signature for breast invasive carcinoma.
    He Y; Li X; Meng Y; Fu S; Cui Y; Shi Y; Du H
    J Cell Biochem; 2019 Oct; 120(10):16692-16702. PubMed ID: 31095790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
    Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a RNA-Seq Based 8-Long Non-Coding RNA Signature Predicting Survival in Esophageal Cancer.
    Fan Q; Liu B
    Med Sci Monit; 2016 Dec; 22():5163-5172. PubMed ID: 28028307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
    Fan CN; Ma L; Liu N
    J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome-wide screening and cohorts validation identifying novel lncRNAs as prognostic biomarkers for clear cell renal cell carcinoma.
    Zhang C; Huang D; Liu A; Xu Y; Na R; Xu D
    J Cell Biochem; 2020 Mar; 121(3):2559-2570. PubMed ID: 31646670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
    Peng W; Wu J; Feng J
    Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
    Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
    J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
    Zhou M; Zhang Z; Zhao H; Bao S; Sun J
    BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An eight-long noncoding RNA expression signature for colorectal cancer patients' prognosis.
    Zhang L; Chen S; Wang B; Su Y; Li S; Liu G; Zhang X
    J Cell Biochem; 2019 Apr; 120(4):5636-5643. PubMed ID: 30320902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
    Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
    Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma.
    Meng X; Fang E; Zhao X; Feng J
    Cancer Med; 2020 Jun; 9(11):3800-3815. PubMed ID: 32216054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a novel six-long non-coding RNA signature predicting survival of colorectal cancer patients.
    Fan Q; Liu B
    J Cell Biochem; 2018 Apr; 119(4):3574-3585. PubMed ID: 29227531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer.
    Liu Z; Mi M; Li X; Zheng X; Wu G; Zhang L
    J Cell Mol Med; 2020 Nov; 24(21):12444-12456. PubMed ID: 32967061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
    Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
    Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A three-lncRNA expression signature predicts survival in head and neck squamous cell carcinoma (HNSCC).
    Wang P; Jin M; Sun CH; Yang L; Li YS; Wang X; Sun YN; Tian LL; Liu M
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30355656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.